Abstract
Continuous infusion of intrajejunal levodopa/carbidopa gel (CIILG) for advanced Parkinson's disease (PD) has been proved to be beneficial on motor complications, non-motor symptoms and quality of life in the short-term follow-up. Aim of this two-center, retrospective, open-label study was to evaluate the long-term effect of CIILG on patients' condition and caregivers' quality of life.
Lingua originale | English |
---|---|
pagine (da-a) | 79-89 |
Numero di pagine | 11 |
Rivista | European Review for Medical and Pharmacological Sciences |
Volume | 16 |
Stato di pubblicazione | Pubblicato - 2012 |
Keywords
- Adult
- Aged
- Antiparkinson Agents
- Caregivers
- Cohort Studies
- Disability Evaluation
- Female
- Humans
- Infusions, Parenteral
- Jejunum
- Levodopa
- Male
- Middle Aged
- Neuropsychological Tests
- Parkinson Disease
- Quality of Life
- Retrospective Studies
- Treatment Outcome